Madrigal’s Rezdiffra Cuts LDL-C Up To 50% and Lp(a) by 62.5% in MASH
MDGL•Madrigal Pharmaceuticals presented Phase 3 and real-world analyses showing Rezdiffra reduced LDL-C by up to 50% and Lp(a) by up to 62.5% and improved ANTICIPATE-NASH scores by 37.6% over two years in MASH patients. Real-world data showed 49% of patients achieved ≥25% liver stiffness reduction over nine months.
1. Phase 3 MAESTRO Lipid Improvements
A secondary analysis of the Phase 3 MAESTRO trials showed that among patients on Rezdiffra plus statins (n=473), 44.4% with baseline LDL-C ≥70 mg/dL shifted below that threshold and 50.0% with baseline LDL-C ≥100 mg/dL shifted below 100 mg/dL at week 52. In statin-naïve patients (n=493), 13.8% shifted LDL-C <70 mg/dL and 51.5% shifted <100 mg/dL. Lp(a) levels dropped below 30 mg/dL in up to 62.5% of patients, supporting dual liver and cardiovascular risk benefits.
2. ANTICIPATE-NASH Risk Score Reductions in Cirrhosis
In patients with well-compensated MASH cirrhosis (F4c) treated up to two years, the proportion at high risk for clinically significant portal hypertension fell from 75.0% at baseline to 60.3% after one year and 54.5% after two years. Mean ANTICIPATE-NASH risk scores declined by up to 37.6%, with infrequent liver-related events occurring only in those with elevated baseline scores.
3. Real-World Outcomes Support Durable Benefits
Multiple real-world cohorts demonstrated early and sustained improvements in cardiometabolic parameters, liver-related biomarkers and liver stiffness measurements. Notably, 49% of patients achieved at least a 25% reduction in liver stiffness over nine months of Rezdiffra therapy, indicating consistent real-world effectiveness.
